An exploratory randomized control study of secukinumab in the treatment of mildly active thyroid-related eye disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065998

Enrollment

Unknown

Registered

2022-11-21

Start date

2022-11-21

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid-related eye disease

Interventions

secukinumab group:secukinumab

Blank control group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years, no gender restriction; 2. In line with the internationally recognized diagnostic criteria for TAO, the severer eye is in the mildly active stage of TAO; 3. Peripheral blood IL-17A concentration higher than 10 pg/ml; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe cardiac, hepatic and renal insufficiency; 2. Stomach ulcer, stomach bleeding, Crohn's disease or other autoimmune disease; 3. Diabetes, uncontrolled hypertension, mental illness; 4. People with tuberculosis, HIV infection or AIDS; 5. Those who are allergic to secukinumab injection; 6. pregnant or breastfeeding; 7. Those who received radioactive iodine therapy and received hepatitis vaccine 3 months before enrollment; 8. Received systemic immunotherapy for TAO one month before enrollment, including oral or intravenous glucocorticoids, other immunosuppressants, and orbital radiotherapy, etc.; 9. Moderate to severe TAO.

Design outcomes

Primary

Measure	Time frame
Ophthalmology Clinical Evaluation;	—

Countries

China

Contacts

Public ContactJing Sun

Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine

sophiasj@126.com+86 18516204866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026